S
Sharon Forsyth
Researcher at University College London
Publications - 15
Citations - 1162
Sharon Forsyth is an academic researcher from University College London. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 8, co-authored 12 publications receiving 925 citations. Previous affiliations of Sharon Forsyth include Nottingham University Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Ujjal Mallick,Clive Harmer,Beng K. Yap,Jonathan Wadsley,Susan E. M. Clarke,Laura Moss,Alice Nicol,Penelope M. Clark,Kate Farnell,Ralph V McCready,James Smellie,J. A. Franklyn,Rhys John,Christopher M. Nutting,Kate Newbold,Catherine Lemon,Georgina Gerrard,Abdel Abdel-Hamid,John Hardman,Elena Macias,Tom Roques,Stephen Whitaker,Rengarajan Vijayan,Pablo Alvarez,Sandy Beare,Sharon Forsyth,Latha Kadalayil,Allan Hackshaw +27 more
TL;DR: Low-dose radioiodine plus thyrotropin alfa was as effective as high-doseRadioiodine, with a lower rate of adverse events, in a randomized noninferiority trial of patients with differentiated thyroid cancer.
Journal ArticleDOI
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon,Sandra J. Strauss,Jeremy Whelan,Michael F. Leahy,Penella J. Woll,Fiona Cowie,Christian Rothermundt,Zoe Wood,Charlotte Benson,Nasim Ali,Maria Marples,Gareth J. Veal,David Jamieson,Katja Küver,Roberto Tirabosco,Sharon Forsyth,Stephen Nash,Hakim-Moulay Dehbi,Sandy Beare +18 more
TL;DR: This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma and found that the proportion of patients alive and progression free at 24 weeks in the intention-to-treat population did not differ.
Journal ArticleDOI
Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
Allan Hackshaw,Michael Roughton,Sharon Forsyth,Kathryn Monson,Krystyna Reczko,Richard Sainsbury,Michael Baum +6 more
TL;DR: Taking tamoxifen for the recommended 5 years reduces the risk of recurrence or contralateral breast cancer 15 years after starting treatment, particularly among those age 50 to 59 years; women should therefore be encouraged to complete the full course.
Journal ArticleDOI
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
Peter Hoskin,Peter Hoskin,Kirsten Hopkins,Vivek Misra,Tanya Holt,Rhona McMenemin,Danny Dubois,Fiona McKinna,Bernadette Foran,Krishnaswamy Madhavan,Carol MacGregor,Andrew Bates,Noelle O'Rourke,Jason F. Lester,Tim Sevitt,Daniel Roos,Daniel Roos,Sanjay Dixit,Gillian Brown,Seonaid Arnott,Sharon Shibu Thomas,Sharon Forsyth,Sandy Beare,Krystyna Reczko,Allan Hackshaw,Andre Lopes +25 more
TL;DR: Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks).
Journal ArticleDOI
Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
Allan Hackshaw,Michael J. Baum,Tommy Fornander,Bo Nordenskjöld,Antonio Nicolucci,Kathryn Monson,Sharon Forsyth,Krystyna Reczko,Ulla Johansson,Helena Fohlin,Miriam Valentini,Richard Sainsbury +11 more
TL;DR: Two years of goserelin treatment was as effective as 2 years of tamoxifen treatment 15 years after starting therapy, and in women who did and did not take tamoxIFen, there was a marginal potential benefit on these outcomes when gose Relin was added.